INSIGHT Community Registry
We are pleased to announce the launch of the INSIGHT: A Global Ocular Melanoma Patient Registry, a collaborative effort between A Cure In Sight and University of California San Francisco Beckman Eye Center, and the National Organization for Rare Disorders (NORD) to study Ocular Melanoma. A Cure In Sight supports research on rare diseases and how they progress over time natural history studies.
Overview of Research Study
The INSIGHT Registry is more than a versatile online system that securely collects and stores data for medical research; it is a dynamic, participant-driven resource that can empower and unite the Ocular Melanoma Community through shared knowledge. Registry participants not only can complete surveys about their own disease experiences, but also can learn about other participants’ experiences by viewing aggregated survey data. As the registry sponsor, A Cure in Sight will ensure that data privacy and confidentiality are strictly maintained. Participation in the INSIGHT Registry is free and voluntary, and participants may withdraw at any time.
The INSIGHT Registry is a powerful opportunity for individuals with Ocular Melanoma and their family members to contribute directly to research that will enhance our understanding of Ocular Melanoma, thus facilitating the development of new diagnostic and treatment options. Participation is especially vital. Given the rarity of Ocular Melanoma, every patient experience is a unique and invaluable part of the natural history of Ocular Melanoma.
For further information or to join, please click Join the Registry or contact: firstname.lastname@example.org
About A Cure In Sight
A Cure in Sight (ACIS) supports families who have ocular melanoma and focuses on research for a cure. Through public and private partnerships, we provide clear and reliable education information providing a support community to patients and their caregivers.
ACIS educates the public about ocular melanoma, treatment options, and clinical trials that may improve their prognosis, making it less overwhelming.
ACIS is dedicated to ongoing research. We know we can accelerate viable research projects that otherwise would stall and not be completed, missing opportunities to advance research for effective treatments and possibly a cure.